Colestrim/Colestrim Supra Indications/Uses

Primary Hypercholesterolemia or Mixed Dyslipidemia: Colestrim/Colestrim Supra is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, TGs and Apo B and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
160-mg: Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been adequate.
Severe Hypertriglyceridemia: Colestrim/Colestrim Supra is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).
145-mg: Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides (eg, >2,000 mg/dL) may increase risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
160-mg: General Recommendations: Drug therapy is not indicated for patients with type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low-density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hrs is helpful in distinguishing types I, IV and V hyperlipoproteinemia.
The initial treatment for dyslipidemia is dietary therapy specific for type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be important ancillary measure. Disease contributory to hyperlipidemia eg, hypothyroidism or diabetes mellitus should be looked for adequately treated. Estrogen therapy, thiazide diuretics and β-blockers, are sometimes associated with massive rise in plasma triglycerides, especially in subjects with familial hypertriglyceridemia.
The use of drug should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet.